Physiological and pathophysiological functions of SIRT1

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 3, 2009, Pages 386-394

  Wojcik, M ^a   Mac Marcjanek, K ^a   Wozniak, Lucyna A ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

FOXO factors; NAD+ dependent deacetylase; p53; Resveratrol; Sir2; SIRT1

Indexed keywords

CAMBINOL; HYDROLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RESVERATROL; SIRTINOL; SIRTUIN 1; SIRTUIN 2; SPLITOMYCIN; SRT 1720; TRANSCRIPTION FACTOR FKHR; TRICHOSTATIN A; UNCLASSIFIED DRUG; HISTONE DEACETYLASE; INSULIN; SIRTUIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER PREVENTION; CELL CYCLE REGULATION; DEACETYLATION; DNA DAMAGE; DRUG STRUCTURE; GLUCONEOGENESIS; GLYCOLYSIS; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LUNG NON SMALL CELL CANCER; NEUROPROTECTION; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; REVIEW; WHITE ADIPOSE TISSUE; ANIMAL; CATALYSIS; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; METABOLISM; NERVE CELL; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CATALYSIS; CELL SURVIVAL; HISTONE DEACETYLASES; HUMANS; INSULIN; MOLECULAR STRUCTURE; NEURONS; SIRTUINS;

EID: 65349155138     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389557510909030386     Document Type: Review

References (110)

1. Frye, R.A. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP- ribosyltransferase activity. Biochem. Biophys. Res. Commun., 1999, 260, 273-9.
2. Shi, T.; Wang, F.; Stieren, E.; Tong, Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J. Biol. Chem., 2005, 280, 13560-7.
3. Rine, J.; Herskowitz, I. Four genes responsible for a position effect on expression from HML and HMR in Saccharomyces cerevisiae. Genetics, 1987, 116, 9-22.
4. Aparicio, O.M.; Billington, B.L.; Gottschling, D.E. Modifiers of position effect are shared between telomeric and silent mating-type loci in S. cerevisiae. Cell, 1991, 66, 1279-87.
5. Smith, J.S.; Boeke, J.D. An unusual form of transcriptional silencing in yeast ribosomal DNA. Genes Dev., 1997, 11, 241-54.
6. Kaeberlein, M.; McVey, M.; Guarente, L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev., 1999, 13, 2570-80.
7. Tissenbaum, H.A.; Guarente, L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature, 2001, 410, 227-30.
8. Frye, R.A. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem. Biophys. Res. Commun., 2000, 273, 793-8.
9. Vaziri, H.; Dessain, S.K.; Eaton, E.; Imai, S.I.; Frye, R.A.; Pandita, T.K.; Guarente, L.; Weinberg, R,A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell, 2001, 107, 149-59.
10. Cohen, H.Y.; Lavu, S.; Bitterman, K.J.; Hekking, B.; Imahiyerobo, T.A.; Miller, C.; Frye, R.; Ploegh, H.; Kessler, B.M.; Sinclair, D.A. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol. Cell, 2004, 13, 627-38.
11. Brunet, A.; Sweeney, L.B.; Sturgill, J.F.; Chua, K.F.; Greer, P.L.; Lin, Y.; Tran, H.; Ross, S.E.; Mostoslavsky, R.; Cohen, H.Y.; Hu, L.S.; Cheng, H.L.; Jedrychowski, M.P.; Gygi, S.P.; Sinclair, D.A.; Alt, F.W.; Greenberg, M.E. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science, 2004, 303, 2011-5.
12. Motta, M.C.; Divecha, N.; Lemieux, M.; Kamel, C.; Chen, D.; Gu, W.; Bultsma, Y.; McBurney, M.; Guarente, L. Mammalian SIRT1 represses forkhead transcription factors. Cell, 2004, 116, 551-63.
13. Muth, V.; Nadaud, S.; Grummt, I.; Voit, R. Acetylation of TAF(I)68, a subunit of TIF- IB/SL1, activates RNA polymerase I transcription. EMBO J., 2001, 20, 1353-62.
14. Fulco, M.; Schiltz, R.L.; Iezzi, S.; King, M.T.; Zhao, P.; Kashiwaya,Y.; Hoffman, E.; Veech, R.L.; Sartorelli, V. Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol. Cell, 2003, 12, 51-62.
15. Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A.; Mayo, M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J., 2004, 23, 2369-80.
16. Picard, F.; Kurtev, M.; Chung, N.; Topark-Ngarm, A.; Senawong, T.; Machado De Oliveira, R.; Leid, M.; McBurney, M.W.; Guarente, L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature, 2004, 429, 771-6.
17. Rodgers, J.T.; Lerin, C.; Haas, W.; Gygi, S.P.; Spiegelman, B.M.; Puigserver, P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature, 2005, 434, 113-8.
18. Kim, J.E.; Chen, J.; Lou, Z. DBC1 is a negative regulator of SIRT1. Nature, 2008, 451, 583-6.
19. Zhao, W.; Kruse, J.P.; Tang, Y.; Jung, S.Y.; Qin, J.; Gu, W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature, 2008, 451, 587-90.
20. +- dependent histone/protein deacetylases. Biochemistry, 2004, 43, 9877-87.
21. Khan, A.N.; Lewis, P.N. Use of substrate analogs and mutagenesis to study substrate binding and catalysis in the Sir2 family of NAD-dependent protein deacetylases. J. Biol. Chem., 2006, 281, 11702-11.
22. Jackson, M.D.; Denu, J.M. Structural identification of 2′- and 3′-Oacetyl- ADP-ribose as novel metabolites derived from the Sir2 family of beta -NAD+-dependent histone/protein deacetylases. J. Biol. Chem., 2002, 277, 18535-44.
23. Rafty, L.A.; Schmidt, M.T.; Perraud, A.L.; Scharenberg, A.M.; Denu, J.M. Analysis of O-acetyl-ADP-ribose as a target for Nudix ADP-ribose hydrolases. J. Biol. Chem., 2002, 277, 47114-22.
24. +-dependent deacetylases. J. Biol. Chem., 2002, 277, 12632-41.
25. Grubisha, O.; Rafty, L.A.; Takanishi, C.L.; Xu, X.; Tong, L.; Perraud, A.L.; Scharenberg, A.M.; Denu, J.M. Metabolite of SIR2 reaction modulates TRPM2 ion channel. J. Biol. Chem., 2006, 281, 14057-65.
26. Jackson, M.D.; Schmidt, M.T.; Oppenheimer N.J.; Denu, J.M. Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J. Biol. Chem., 2003, 278, 50985-98.
27. Sauve, A.A.; Schramm, V.L. Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry, 2003, 42, 9249-56.
28. Schmidt, M.T.; Smith, B.C.; Jackson, M.D.; Denu, J.M. Coenzyme specificity of Sir2 protein deacetylases: implications for physiological regulation. J. Biol. Chem., 2004, 279, 40122-9.
29. Bitterman, K.J.; Anderson, R.M.; Cohen, H.Y.; Latorre-Esteves, M.; Sinclair, D.A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem., 2002, 277, 45099-107.
30. Grozinger, C.M.; Chao, E.D.; Blackwell, H.E.; Moazed, D.; Schreiber, S.L. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J. Biol. Chem., 2001, 276, 38837-43.
31. Posakony, J.; Hirao, M.; Stevens, S.; Simon, J.A.; Bedalov, A. Inhibitors of Sir2: evaluation of splitomicin analogues. J. Med. Chem., 2004, 47, 2635-44.
32. Heltweg, B.; Gatbonton, T.; Schuler, A.D.; Posakony, J.; Li, H.; Goehle, S.; Kollipara, R.; Depinho, R.A.; Gu, Y.; Simon, J.A.; Bedalov, A. Antitumor activity of a small- molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res., 2006, 66, 4368-77.
33. Borra, M.T.; Smith, B.C.; Denu, J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem., 2005, 280, 17187-95.
34. Olas, B.; Wachowicz, B.; Saluk-Juszczak, J.; Zielinski, T.; Kaca, W.; Buczynski, A. Antioxidant activity of resveratrol in endotoxin-stimulated blood platelets. Cell Biol. Toxicol., 2001, 17, 117-25.
35. Burkitt, M.J.; Duncan, J. Effects of trans-resveratrol on copper-dependent hydroxyl- radical formation and DNA damage: evidence for hydroxyl-radical scavenging and a novel, glutathione-sparing mechanism of action. Arch. Biochem. Biophys., 2000, 381, 253-63.
36. Delmas, D.; Lancon, A.; Colin, D.; Jannin, B.; Latruffe, N. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr. Drug Targets, 2006, 7, 423-42.
37. Aggarwal, B.B.; Bhardwaj, A.; Aggarwal, R.S.; Seeram, N.P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res., 2004, 24, 2783-840.
38. Valenzano, D.R.; Terzibasi, E.; Genade, T.; Cattaneo, A.; Domenici, L.; Cellerino, A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short- lived vertebrate. Curr. Biol., 2006, 16, 296-300.
39. Viswanathan, M.; Kim, S.K.; Berdichevsky, A.; Guarente, L. A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans life span. Dev. Cell, 2005, 9, 605-15.
40. Wood, J.G.; Rogina, B.; Lavu, S.; Howitz, K.; Helfand, S.L.; Tatar, M.; Sinclair, D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature, 2004, 430, 686-9.
41. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.L.; Scherer, B.; Sinclair, D.A. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003, 425, 191-6.
42. Araki, T.; Sasaki, Y.; Milbrandt, J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science, 2004, 305, 1010-3.
43. Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; Westman, E.A.; Caldwell, S.D.; Napper, A.; Curtis, R.; DiStefano, P.S.; Fields, S.; Bedalov, A.; Kennedy, B.K. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem., 2005, 280, 17038-45.
44. Zhao, K.; Chai, X.; Marmorstein, R. Structure of the yeast Hst2 protein deacetylase in ternary complex with 2′-O-acetyl ADP ribose and histone peptide. Structure (Camb.), 2003, 11, 1403-11.
45. Finnin, M.S.; Donigian, J.R.; Pavletich, N.P. Structure of the histone deacetylase SIRT2. Nat. Struct. Biol., 2001, 8, 621-5.
46. Chang, J.H.; Kim, H.C.; Hwang, K.Y.; Lee, J.W.; Jackson, S.P.; Bell, S.D.; Cho, Y. Structural basis for the NAD-dependent deacetylase mechanism of Sir2. J. Biol. Chem., 2002, 277, 34489-98.
47. Min, J.; Landry, J.; Sternglanz, R.; Xu, R.M. Crystal structure of a SIR2 homolog- NAD complex. Cell, 2001, 105, 269-79.
48. Avalos, J.L.; Boeke, J.D.; Wolberger, C. Structural basis for the mechanism and regulation of Sir2 enzymes. Mol. Cell, 2004, 13, 639-48.
49. Avalos, J.L.; Celic, I.; Muhammad, S.; Cosgrove, M.S.; Boeke, J.D.; Wolberger, C. Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol. Cell, 2002, 10, 523-35.
50. Sherman, J.M.; Stone, E.M.; Freeman-Cook, L.L.; Brachmann, C.B.; Boeke, J.D.; Pillus, L. The conserved core of a human SIR2 homologue functions in yeast silencing. Mol. Biol. Cell, 1999, 10, 3045-59.
51. Sawada, M.; Sun, W.; Hayes, P.; Leskov, K.; Boothman, D.A.; Matsuyama, S. Ku70 suppresses the apoptotic translocation of Bax to mitochondria. Nat. Cell Biol., 2003, 5, 320-9.
52. Greer, E.L.; Brunet, A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene, 2005, 24, 7410-25.
53. Tang, T.T.; Dowbenko, D.; Jackson, A.; Toney, L.; Lewin, D.A.; Dent, A.L.; Lasky, L.A. The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor. J. Biol. Chem., 2002, 277, 14255-65.
54. Nakamura, N.; Ramaswamy, S.; Vazquez, F.; Signoretti, S.; Loda, M.; Sellers, W.R. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol. Cell Biol., 2000, 20, 8969-82.
55. Kops, G.J.; Medema, R.H.; Glassford, J.; Essers, M.A.; Dijkers, P.F.; Coffer, P.J.; Lam, E.W.; Burgering, B.M. Control of cell cycle exit and entry by protein kinase B- regulated forkhead transcription factors. Mol. Cell Biol., 2002, 22, 2025-36.
56. Tran, H.; Brunet, A.; Grenier, J.M.; Datta, S.R.; Fornace A.J.; DiStefano, P.S.; Chiang, L.W.; Greenberg, M.E. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science, 2002, 296, 530-4.
57. Kops, G.J.; Dansen, T.B.; Polderman, P.E.; Saarloos, I.; Wirtz, K.W.; Coffer, P.J.; Huang, T.T.; Bos, J.L.; Medema, R.H.; Burgering, B.M. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature, 2002, 419, 316-21.
58. Hribal, M.L.; Nakae, J.; Kitamura, T.; Shutter, J.R.; Accili, D. Regulation of insulin- like growth factor-dependent myoblast differentiation by Foxo forkhead transcription factors. J. Cell Biol., 2003, 162, 535-41.
59. Nakae, J.; Kitamura, T.; Kitamura, Y.; Biggs, W.H.; Arden, K.C.; Accili, D. The forkhead transcription factor Foxo1 regulates adipocyte differentiation. Dev. Cell, 2003, 4, 119-29.
60. Daitoku, H.; Yamagata, K.; Matsuzaki, H.; Hatta, M.; Fukamizu, A. Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR. Diabetes, 2003, 52, 642-9.
61. Brunet, A.; Bonni, A.; Zigmond, M.J.; Lin, M.Z.; Juo, P.; Hu, L.S.; Anderson, M.J.; Arden, K.C.; Blenis, J.; Greenberg, M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 1999, 96, 857-68.
62. van der Horst, A.; Tertoolen, L.G.; de Vries-Smits, L.M.; Frye, R.A.; Medema, R.H.; Burgering, B.M. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J. Biol. Chem., 2004, 279, 28873-9.
63. Yang, Y.; Hou, H.; Haller, E.M.; Nicosia, S.V.; Bai, W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J., 2005, 24, 1021-32.
64. Kitamura, Y.I.; Kitamura, T., Kruse, J.P.; Raum, J.C.; Stein, R.; Gu, W.; Accili, D. FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab., 2005, 2, 153-63.
65. Barak, Y.T.; Juven, T.; Haffner, R.; Oren, M. mdm2 expression is induced by wild type p53 activity. EMBO J., 1993, 12, 461-8.
66. El-Deiry, W.S.; Tokino, T.; Velculescu, V.E.; Levy, D.B.; Parson, R.; Trent, J.M.; Lin, D.; Mercer, W.E.; Kinzler, K.W.; Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 1993, 75, 817-25.
67. Okamoto, K.; Beach, D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J., 1994, 13, 4816-22.
68. Buckbinder, L.; Talbott, R.; Velasco-Miguel, S.; Takenaka, I.; Faha, B.; Seizinger, B.R; Kley, N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature, 1995, 377, 646-9.
69. Miyashita, T.; Reed, J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 1995, 80, 293-9.
70. Shieh, S.Y.; Ahn, J.; Tamai, K.; Taya, Y.; Prives, C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev., 2000, 14, 289-300.
71. Giaccia, AJ, Kastan, M. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev., 1998, 12, 2973-83.
72. Lambert, P.F.; Kashanchi, F.; Radonovich, M.F.; Shiekhattar, R.; Brady, J.N. Phosphorylation of p53 serine 15 increases interaction with CBP. J. Biol. Chem., 1998, 273, 33048-53.
73. Gu, W.; Roeder, R. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell, 1997, 90, 595-600.
74. Luo, J.; Li, M.; Tang, Y.; Laszkowska, M.; Roeder, R.G.; Gu, W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 2004, 101, 2259-64.
75. Liu, L.; Scolnick, D.; Trievel, R.C.; Zhang, H.B.; Marmorstein, R.; Halazonetis, T.D.; Berger, S.L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell Biol., 1999, 19, 1202-9.
76. Lill, N.L.; Grossman, S.; Ginsberg, D.; DeCaprio, J.; Livingston, D.M. Binding and modulation of p53 by p300/CBP coactivators. Nature, 1997, 387, 823-7.
77. Sakaguchi, K.; Herrera, J.E.; Saito, S.; Miki, T.; Bustin, M.; Vassilev, A.; Anderson, C.W.; Appella, E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev., 1998, 12, 2831-41.
78. Luo, J.; Nikolaev, A.Y.; Imai, S.; Chen, D.; Su, F.; Shiloh, A.; Guarente, L.; Gu, W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell, 2001, 107, 137-48.
79. Luo, J.; Su, F.; Chen, D.; Shiloh, A.; Gu, W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature, 2000, 408, 377-81.
80. Cheng, H.L.; Mostoslavsky, R.; Saito, S.; Manis, J.P.; Gu, Y.; Patel, P.; Bronson, R.; Appella, E.; Alt, F.W.; Chua, K.F. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. U S A., 2003, 100, 10794-9.
81. Ford, J.; Jiang, M.; Milner, J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res., 2005, 65, 10457-63.
82. Karin, M.; Lin, A. NF-kappaB at the crossroads of life and death. Nat.Immunol., 2002, 3, 221-7.
83. Sheppard, K.A.; Rose, D.W.; Haque, Z.K.; Kurokawa, R.; McInerney, E.; Westin, S.; Thanos, D.; Rosenfeld, M.G.; Glass, C.K.; Collins, T. Transcriptional activation by NF-kappaB requires multiple coactivators. Mol. Cell Biol., 1999, 19, 6367-78.
84. Sheppard, K.A.; Phelps, K.M.; Williams, A.J.; Thanos, D.; Glass, C.K.; Rosenfeld, M.G.; Gerritsen, M.E.; Collins, T. Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J. Biol. Chem., 1998, 273, 29291-4.
85. Kiernan, R.; Brès, V.; Ng, R.W.; Coudart, M.P.; El Messaoudi, S.; Sardet, C.; Jin, D.Y.; Emiliani, S.; Benkirane, M. Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J. Biol. Chem., 2003, 278, 2758-66.
86. Chen, L.F.; Mu, Y.; Greene, W.C. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J., 2002, 21, 6539-48.
87. Narayanan, B.A.; Narayanan, N.K.; Stoner, G.D.; Bullock, B.P. Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. Life Sci., 2002, 70, 1821-39.
88. Culmsee, C.; Siewe, J.; Junker, V.; Retiounskaia, M.; Schwarz, S.; Camandola, S.; El- Metainy, S.; Behnke, H.; Mattson, M.P.; Krieglstein, J. Reciprocal inhibition of p53 and nuclear factor-kappaB transcriptional activities determines cell survival or death in neurons. J. Neurosci., 2003, 23, 8586-95.
89. Zhong, H.; May, M.J.; Jimi, E.; Ghosh, S. The phosphorylation status of nuclear NF-kappaB determines its association with CBP/p300 or HDAC-1. Mol. Cell, 2002, 9, 625-39.
90. Quinn, P.G.; Yeagley, D. Insulin regulation of PEPCK gene expression: a model for rapid and reversible modulation. Curr. Drug Targets Immune Endocr. Metabol. Disord., 2005, 5, 423-37.
91. Bordone, L.; Motta, M.C.; Picard, F.; Robinson, A.; Jhala, U.S.; Apfeld, J.; McDonagh, T.; Lemieux, M.; McBurney, M.; Szilvasi, A.; Easlon, E.J.; Lin, S.J.; Guarente, L. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol., 2006, 4, e31.
92. Moynihan, K.A.; Grimm, A.A.; Plueger, M.M.; Bernal-Mizrachi, E.; Ford, E.; Cras- Méneur, C.; Permutt, M.A.; Imai, S. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab., 2005, 2, 105-17.
93. Chan, C.B.; Saleh, M.C.; Koshkin, V.; Wheeler, M.B. Uncoupling protein 2 and islet function. Diabetes, 2004, 53 (Suppl. 1), 136-42.
94. Chan, C.B.; MacDonald, P.E.; Saleh, M.C.; Johns, D.C.; Marban, E.; Wheeler, M.B. Overexpression of uncoupling protein 2 inhibits glucose-stimulated insulin secretion from rat islets. Diabetes, 1999, 48, 1482-6.
95. Chawla, A.; Schwarz, E.J.; Dimaculangen, D.D.; Lazar, MA. Peroxisome proliferator- activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology, 1994, 135, 798-800.
96. Tontonoz, P.; Hu, E.; Spiegelman, B.M. Stimulation of adipogenesis in fibroblasts by PPARgamma2, a lipid-activated transcription factor. Cell, 1994, 79, 1147-56.
97. Tontonoz, P.; Hu, E.; Graves, R.A.; Budavari, A.I.; Spiegelman, B.M. mPPARgamma2: tissue-specific regulator of an adipocyte enhancer. Genes Dev., 1994, 8, 1224-34.
98. Tontonoz, P.; Hu, E.; Devine, J.; Beale, E.G.; Spiegelman, B.M. PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol. Cell Biol., 1995, 15, 351-7.
99. Schoonjans, K.; Peinado-Onsurbe, J.; Lefebvre, A.M.; Heyman, R.A.; Briggs, M.; Deeb, S.; Staels, B.; Auwerx, PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. J., 1996, 15, 5336-48.
100. Dowell, P.; Otto, T.C.; Adi, S.; Lane, M.D. Convergence of peroxisome proliferator- activated receptor gamma and Foxo1 signaling pathways. J. Biol. Chem., 2003, 278, 45485-91.
101. Stokin, G.B.; Lillo, C.; Falzone, T.L.; Brusch, R.G.; Rockenstein, E.; Mount, S.L.; Raman, R.; Davies, P.; Masliah, E.; Williams, D.S.; Goldstein, L.S. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science, 2005, 307, 1282-8.
102. Fischer, L.R.; Culver, D.G.; Tennant, P.; Davis, A.A.; Wang, M.; Castellano-Sanchez, A.; Khan, J.; Polak, M.A.; Glass, J.D. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol., 2004, 185, 232-40.
103. Wang, J.; Zhai, Q.; Chen, Y.; Lin, E.; Gu, W.; McBurney, M.W.; He, Z. A local mechanism mediates NAD-dependent protection of axon degeneration. J. Cell Biol., 2005, 170, 349-55.
104. Gandy, S. Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease. Neurobiol. Aging, 2002, 23, 1009-16.
105. Qin, W.; Yang, T.; Ho, L.; Zhao, Z.; Wang, J.; Chen, L.; Zhao, W.; Thiyagarajan, M.; MacGrogan, D.; Rodgers, J.T.; Puigserver, P.; Sadoshima, J.; Deng, H.; Pedrini, S.; Gandy, S.; Sauve, A.A.; Pasinetti, G.M. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem., 2006, 281, 21745-54.
106. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P.J.; Poosala, S.; Becker, K.G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K.W.; Spencer, R.G.; Lakatta, E.G.; Le Couteur, D.; Shaw, R.J.; Navas, P.; Puigserver, P.; Ingram, D.K.; de Cabo, R.; Sinclair, D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444, 337-42.
107. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; Geny, B.; Laakso, M.; Puigserver, P.; Auwerx, J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 2006, 127, 1109-22.
108. Pearson, K.J.; Baur, J.A.; Lewis, K.N.; Peshkin, L.; Price, N.L.; Labinsky, N.; Swindell, W.R.; Kamara, D.; Minor, R.K.; Perez, E.; Jamieson, H.A.; Zhang, Y.; Dunn, S.R.; Sharma, K.; Pleshko, N.; Woollett, L.A.; Csiszar, A.; Ikeno, Y.; Le Couteur, D.; Elliott, P.J.; Becker, K.G.; Navas, P.; Ingram, D.K.; Wolf, N.S.; Ungvari, Z.; Sinclair, D.A.; de Cabo, R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab., 2008, 8, 157-68.
109. Milne, J.C.; Lambert, P.D.; Schenk, S.; Carney, D.P.; Smith, J.J.; Gagne, D.J.; Jin, L.; Boss, O.; Perni, R.B.; Vu, C.B.; Bemis, J.E.; Xie, R.; Disch, J.S.; Ng, P.Y.; Nunes, J.J.; Lynch, A.V.; Yang, H.; Galonek, H.; Israelian, K.; Choy, W.; Iffland, A.; Lavu, S.; Medvedik, O.; Sinclair, D.A.; Olefsky, J.M.; Jirousek, M.R.; Elliott, P.J.; Westphal, C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature, 2007, 450, 712-6.
110. Feige, J. N.; Lagouge, M.; Canto, C.; Strehle, A.; Houten, S. M.; Milne, J.C.; Lambert, P.D.; Mataki, Ch.; Elliot, P.J.; Auwerx, J. SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab., 2008, 8, 347-358.